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The purpose of the experimental study was to design a sustained release film formulation of metformin 
hydrochloride. In this study a transdermal film has been prepared by incorporating hydrophilic polymers like 
HPMC and PVA in combination of different ratios. The prepared film were subjected for different evaluation 
parameters like swelling index study, surface pH, drug content analysis, thickness of film, folding endurance 
study, drug release study. Results of evaluation of all the film was found satisfactory. Again further study 
needs to be conducted to stabilize the formulations.  
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INTRODUCTION 
Among the several lifestyle diseases, Non insulin 
dependent diabetes mellitus is very common. It  may 
also leads other health related problems like high BP, 
lipid disorder, cardiac disease, nephritis , Retinopathy, 
muscle weakness &obesity1. It’s a chronic metabolic 
disorder characterized by a high blood glucose 
concentration (hyperglycemia) caused due to deficiency 
insulin.2 As per WHO around 347 million people 
worldwide having diabetes. In 2004, an estimated 3.4 
million people died from consequences of fasting high 
blood sugar. A similar number of deaths have been 
estimated for 2010.3 WHO projects that diabetes will be 
the 7th leading cause of death in 2030.4  
Metformin is the only antidiabetic drug that has been 
conclusively shown to prevent the cardiovascular 
complications of diabetes. It helps to reduce LDL 
cholesterol and triglyceride levels, and is not associated 
with weight gain5. As of 2010, metformin is one of only 
two oral antidiabetics in the World Health Organization 
Model List of Essential Medicines7  Despite of the 
rationality in use, metformin reported to have several 
adverse effects like gastrointestinal upset, lactic 
acidosis, vomiting abdominal pain, anorexia, nausea, 
metallic taste and mild diarrhoea etc when administered 
orally6.  
In the year 1979 Food and Drug Administration 
approved the first transdermal drug delivery system. 
Transdermal Drug Delivery System is one which 
delivers the active ingredients by the means of skin. It’s 
a most popular novel approach and consider as 
successful alternative to systemic drug delivery. 
Transdermal delivery systems have proved 
advantageous for delivery of selected drugs, such as 
estrogens, testosterone, clonidine, nitroglycerin, 
scopolamine, fentanyl, and nicotine. Compared with 
oral dosage forms, these systems offer not only 
improved patient compliance, but also superior 
uniformity of drug concentrations in plasma throughout 
their duration of use. Most transdermal patches are 
designed to release the active ingredient at a zero-order 
rate for a period of several hours to days following 
application to the skin. This kind of delivery systems 
especially advantageous for prophylactic treatment or 
maintenance therapy in chronic conditions where the 
patient is otherwise required to carry oral medications 
and remember to take them several times a day. 
In consideration of above fact current study has been 
designed to develop transdermal film of the metformin 
hydrochloride. The film was fabricated using different 
combination of polymers namely HPMC and PVA. 
 
MATERIAL AND METHODS 
Hydroxyl propyl methyl cellulose (HPMC), polyvinyl 
alcohol and glycerin were procured from S.D. Fine 
chem. Ltd. Mumbai. Metformin hydrochloride was 
received as generous gift sample from Sun 
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Pharmaceuticals Ltd., Baroda, Gujarat. All other 
chemicals and solvents used were of analytical grade. 
 
PREPARATION OF TRANSDERMAL FILM 
The transdermal film of metformin hydrochloride was 
prepared using different concentration of polymers like 
HPMC and PVA. The calculated amount of polymer 
was shocked in 20 ml of distilled water for 24 hours. 
Then drug (metformin hydrochloride 500 mg) was 
added in the polymeric solution with continues stirring. 
Desire quantity of glycerin was added in homogenized 
drug polymer solution and kept aside for some time at 
room temperature .The prepared formulation was then 
transferred into Petridis and kept for drying in room 
temperature and followed by dryer at around 45oc 
temperature. The dried film was then cut into desire 
pieces, wrapped in aluminum foil and was kept in 
desiccators until further use9. The formula of the 
prepared films is mention in table no. I 
 
EVALUATION OF TRANSDERMAL FILMS 
Weight Uniformity 
The prepared films are dried for 4 hours at 60˚C before 
performing the test. A specific part of a definite 
dimension is cut from various parts of the patch and 
weighed on a digital balance. The average weight and 
standard deviation values are then calculated.  
 
Thickness of the films 
The thickness of the drug loaded film is determined at 
different points by using a digital micrometer. 
 
Folding Endurance 
Folding endurance of the 2x2cm films was determined 
by repeatedly folding one film at the same place till it 
broke or folded upto 300 times manually, which was 
considered satisfactory to reveal good film properties. 
The number of times of film could be folded at the same 
place without breaking gave the value of the folding 
endurance. This test was done on three individual films 
of each formulation batches.13 
 
Surface pH of Film 
For determination of surface pH three films of each 
formulation were selected randomly and are allowed to 
swell for 2 hours on the surface of previously prepared 
1% agar plate. The surface pH was measured by using a 
pH paper placed on the surface of swollen film.14 
 
Swelling Index 
Films were weighed individually (designated as W1) 
and placed separately in 1% agar gel plates, incubated at 
37°C ± 1°C, and examined for any physical changes. At 
regular 1hour time intervals until 3 hours, films were 
removed from the gel plates and excess surface water 
was removed carefully using the filter paper. The 
swollen patches were then reweighed (W2), and the 
swelling index (SI) was calculated using the following 
formula.10 
𝑆𝐼 =
𝑊2−𝑊1
𝑊1
× 100 
 
Content Uniformity 
Drug content uniformity was determined by dissolving 
each 2x2cm films of different batches in 100mL 
distilled water. The whole content was then shake 
continuously 5 hours with the help of rotary shaker and 
then kept aside for 24 hours. Then the solution was filter 
with Whatman filter paper (0.45 μm). Form the filtrate 
5ml solution was taken and suitably diluted with 
distilled water and analyzed using UV 
spectrophotometer.12 
 
In vitro Drug Release Study 
The in vitro release study was performed using Franz 
diffusion cell. A piece of film having definite size was 
used for this study. The dissolution media consist of 
500ml of distilled water. The release study was 
performed in 500ml distilled water as dissolution 
medium and a rotation speed of 50 rpm and temperature 
of 37°C ± 1°C was maintained throughout the 
experiment. The study was carried out for 8 hours. After 
every 1hr interval 5ml of sample was withdrawn from 
receptor compartment and the same was replaced back 
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to donor compartment. Each withdrawn sample was 
filtered, diluted suitably and then analyzed 
spectrophotometrically11. 
 
Table No. I Formula of Different Formulation Batches 
S. No. Ingredients 
Formulation batch 
F1 F2 F3 F4 
1.  Metformin hydrochloride(g) 0.5 0.5 0.5 0.5 
2.  HPMC (g) 2 1.66 1.33 2.4 
3.  PVA (g) 2 1.33 1.66 1.6 
4.  Glycerin(ml) 0.3 0.3 0.3 0.3 
5.  Distill water(ml) 100 100 100 100 
 
Table No. II Different Physical Parameter of All the Prepared Films 
S. 
No 
Batch 
code 
Weight 
variation (mg) 
Folding 
endurance 
Swelling 
index (%) 
Thickness 
(mm) 
Surface  
Ph 
Drug content 
1.  F1 230 >300 350 0.62±0.03 6.5 48.02 
2.  F2 260 >300 80 0.85±0.02 7 25.48 
3.  F3 320 >300 200 0.73±0.04 7 35.77 
4.  F4 210 >300 60 0.81±0.03 6 40.18 
 
RESULTS AND DISCUSSION 
The main goal of this experimental work was to find out 
the in-vitro efficiency of the prepared dosage form to 
deliver metformin effectively. Four set (F1-F4) of 
transdermal film were prepared and evaluated 
accordingly. Formulas of prepared formulation are 
presented in Table I. And the Physical characteristics of 
all the prepared films are represented in Table II. The 
prepared films were of around 0.75 mm in thickness. 
The weight of films was found within the range from 
210 to 320 mg. Folding endurance capacity of all the 
formulations were found > 300  that can be consider as 
a sign of good flexibility. The swelling behavior study 
was performed to determine the percentage of swelling 
and found within the satisfactory range. Based on the 
results of release study, as shown in (Fig-1) it can be 
state that, all the formulation showing first order 
followed by zero- order release profile. More than 80% 
of drug gets release after 8 hrs time interval. It has been 
found that drug release from all the formulations were 
uniform and prolong, follows sustained release pattern.  
 
CONCLUSION 
All the prepared formulations show satisfactory results 
in terms of the evaluated parameters. The outcomes of 
the current experiments advocate a rational guideline for 
formulating a sustained release transdermal therapeutic 
system of metformin hydrochloride for effective 
therapy. Further this experimental work shall be carried 
out for the estimation of several other important 
parameters before commercialization of product. 
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